Renowned reproductive biology expert Wei Yan, MD, PhD, leads class of recruits

LOS ANGELES — The Lundquist Institute has added six new investigators to its distinguished research faculty, headlined by Wei Yan, MD, PhD, an internationally renowned investigator in reproductive biology. This new class of recruits will arrive on campus between June and September of 2020, with dedicated research space throughout the 11.5-acre campus.

Los Angeles-area biomedical research institute participates in 2000-person trial for potential coronavirus treatment

Investigator(s): Eric Daar, MD

LOS ANGELES (May 6, 2020) — Today, researchers at The Lundquist Institute began a randomized, double-blind, placebo-controlled clinical trial designed to find out whether hydroxychloroquine and azithromycin reduce hospitalization and/or death in individuals suffering from COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. This trial, sponsored by the National Institutes for Health, will include 2,000 adults with symptomatic SARS-CoV-2 infections. Under the direction of Dr.

New institute brings together renowned experts focused on biggest health concerns facing women and children

Investigator(s): Ruey-Kang Chang, MD

LOS ANGELES – Today, The Lundquist Institute, formerly known as the Los Angeles Biomedical Research Institute (LA BioMed), located at Harbor-UCLA Medical Center, held the inaugural meeting of its Institute for Women’s and Children’s Health (IWCH).

Physical inactivity is best predictor of decline in COPD patients, US’ 4th-leading cause of death 

Investigator(s): Harry Rossiter, PhD

LOS ANGELES — Dr. Harry Rossiter, an investigator at The Lundquist Institute (formerly known as LA BioMed) was among the recipients of a $1.55 million grant award from the National Institutes of Health (NIH) to study muscle dysfunction in patients with chronic obstructive pulmonary disease (COPD), the fourth-leading cause of death in the United States.

Tepezza™ is first and only FDA-approved treatment for Thyroid Eye Disease. Approval marks fourth FDA-approved product containing technologies created at The Lundquist Institute.

Investigator(s): The Lundquist Institute

LOS ANGELES — The U.S. Food and Drug Administration (FDA) approved Tepezza™ for the treatment of Thyroid Eye Disease (TED) on January 21, marking the fourth FDA-approved product containing technologies pioneered at The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), in the last 17 years—and the third in the last five years.

Longtime business development executive to oversee incubator facilities and biotech park planning

Investigator(s): The Lundquist Institute

LOS ANGELES – The Lundquist Institute, formerly the Los Angeles Biomedical Research Institute (LA BioMed), has promoted Keith Bronson Hoffman, PhD to Senior Vice President of Business Development and Technology Transfer.

The Lundquist Institute research offers lessons for communities from California to Australia

Investigator(s): Merritt Schreiber

LOS ANGELES — An investigator from The Lundquist Institute has demonstrated a way to limit the effects of post-traumatic stress disorder in those affected by wildfires through early intervention and triage using a web-based app, providing valuable insight for medical professionals and first responders dealing with the aftermath of another devastating fire season.

Abstaining from cocaine use can help HIV-positive people with cognition 

Investigator(s): Matthew Wright, PhD

LOS ANGELES — A new study from The Lundquist Institute shows that cocaine use exacerbates memory loss and other neuropsychological impairments among people with HIV, providing new insight into the effects of cocaine and more information to better treat HIV-positive individuals. 

New study from The Lundquist Institute can help stop the spread of superbugs

LOS ANGELES — A new study from The Lundquist Institute shows a reliable, repeatable way to reduce the unnecessary use of antibiotics in emergency departments and urgent care centers. Overusing antibiotics does not help patients, wastes money, and more importantly is accelerating the epidemic of drug-resistant bacteria—or “superbugs.”

Study from The Lundquist Institute finds sub-dissociative doses useful for acute flare-ups

Investigator(s): David Tanen, PhD

LOS ANGELES — A study from The Lundquist Institute shows that modest doses of ketamine can effectively treat acute exacerbations of chronic pain, providing physicians with another proven option aside from addictive opioids, which have devastated communities and resulted in thousands of early deaths in recent years.